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Abstract
Single nucleotide polymorphisms in the gene encoding the protein tyrosine phosphatase TCPTP (encoded by PTPN2) have
been linked with the development of autoimmunity. Here we have used Cre/LoxP recombination to generate Ptpn2
ex22/ex22
mice with a global deficiency in TCPTP on a C57BL/6 background and compared the phenotype of these mice to Ptpn2
2/2
mice (BALB/c-129SJ) generated previously by homologous recombination and backcrossed onto the BALB/c background.
Ptpn2
ex22/ex22 mice exhibited growth retardation and a median survival of 32 days, as compared to 21 days for Ptpn2
2/2
(BALB/c) mice, but the overt signs of morbidity (hunched posture, piloerection, decreased mobility and diarrhoea) evident in
Ptpn2
2/2 (BALB/c) mice were not detected in Ptpn2
ex22/ex22 mice. At 14 days of age, bone development was delayed in
Ptpn2
2/2 (BALB/c) mice. This was associated with increased trabecular bone mass and decreased bone remodeling,
a phenotype that was not evident in Ptpn2
ex22/ex22 mice. Ptpn2
ex22/ex22 mice had defects in erythropoiesis and B cell
development as evident in Ptpn2
2/2 (BALB/c) mice, but not splenomegaly and did not exhibit an accumulation of myeloid
cells in the spleen as seen in Ptpn2
2/2 (BALB/c) mice. Moreover, thymic atrophy, another feature of Ptpn2
2/2 (BALB/c) mice,
was delayed in Ptpn2
ex22/ex22 mice and preceded by an increase in thymocyte positive selection and a concomitant increase
in lymph node T cells. Backcrossing Ptpn2
2/2 (BALB/c) mice onto the C57BL/6 background largely recapitulated the
phenotype of Ptpn2
ex22/ex22 mice. Taken together these results reaffirm TCPTP’s important role in lymphocyte development
and indicate that the effects on morbidity, mortality, bone development and the myeloid compartment are strain-
dependent.
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Introduction
T cell protein tyrosine phosphatase (TCPTP) encoded by
PTPN2 is an intracellular tyrosine-specific protein tyrosine
phosphatase (PTP) [1]. TCPTP is expressed ubiquitously, but it
is most abundant in cells of hematopoietic origin where it serves as
a key regulator of hematopoiesis and immune and inflammatory
responses [1]. Genome-wide association studies have linked
PTPN2 single nucleotide polymorphisms (SNPs) with the de-
velopment of autoimmune diseases including inflammatory bowel
disease, type 1 diabetes and rheumatoid arthritis [2,3,4]. Recent
studies have reported that type 1 diabetes-associated PTPN2
intronic SNPs may result in decreased PTPN2 messenger RNA
[5]. Moreover, PTPN2 is deleted in 6% [6] of all T cell acute
lymphoblastic leukemias, in particular in those overexpressing the
TLX1 transcription factor oncogene, promoting proliferation and
enhancing cytokine sensitivity [7]. In addition, alterations in
TCPTP expression may be associated with several other
malignancies and inflammatory diseases [8,9,10,11].
Several TCPTP substrates have been identified including
receptor protein tyrosine kinases (PTKs), such as those for
epidermal growth factor [12,13,14], insulin [15,16,17] and colony
stimulating factor-1 [18], cytosolic PTKs, including Janus-
activated kinases (JAK)-1 and -3 [19] and c-Src [6,20], and
PTK substrates such the adaptor protein p52
Shc [14] and signal
transducers and activators of transcription (STAT)-1, -3, 5, and -6
[9,19,20,21,22,23]. In keeping with TCPTP being a key regulator
of immune and inflammatory responses TCPTP has been shown
to attenuate cytokine-induced JAK/STAT signaling in different
cell types, including lymphocytes and myeloid cells [18] and to
regulate TNF-induced inflammatory responses by attenuating c-
Src-induced mitogen-activated protein kinase signaling [6]. More
recently, TCPTP has been shown to be important in T cell
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in T cells exhibit enhanced thymocyte positive selection and
enhanced T cell receptor-mediated T cell responses in vivo [24].
TCPTP’s role in hematopoiesis, immunity and inflammation is
highlighted by the phenotype of Ptpn2
2/2 mice on a mixed
BALB/c-129SJ background [25]; mice appear physically normal
albeit slightly smaller at 10–14 days of age, but thereon exhibit
growth retardation, a hunched posture, piloerection, decreased
mobility and diarrhoea and overt signs of wasting disease,
succumbing by 3–5 weeks of age [25]. Ptpn2
2/2 (BALB/c-
129SJ) mice are characterized by widespread mononuclear
infiltrates in non-lymphoid tissues and elevated serum interferon
(IFN) c levels by 19 days of age [26]. Consistent with the
inflammatory phenotype, Ptpn2
2/2 (BALB/c-129SJ) mice are
more susceptible to endotoxic shock and macrophages are
hypersensitive to lipopolysaccharide [26] and IFNc [19], whereas
Ptpn2
+/2 (BALB/c-129SJ) mice are hypersensitive to dextran
sulphate sodium (DSS) and the development of colitis [27].
Ptpn2
2/2 (BALB/c-129SJ) mice exhibit defects in hematopoiesis,
in particular in B cell development and erythropoiesis and develop
severe anemia [25]. The defect in B cell development is thought to
be attributable, at least in part, to a bone marrow stromal defect
and the abnormal secretion of IFNc by bone marrow stromal cells
[28]. Ptpn2
2/2 (BALB/c-129SJ) mice develop thymic atrophy
associated with a drop in double positive (CD4+CD8+) thymo-
cytes, lymphadenopathy and splenomegaly, the latter being
associated with an accumulation of myeloid cells and the
sequestration of red blood cells [25].
The Ptpn2
2/2 (BALB/c-129SJ) mice were generated more than
ten years ago using a homologous recombination approach that
resulted in the deletion of approximately 9 kb of genomic
sequence, including 1.5 exons (encoding residues 64–121) from
the TCPTP catalytic domain, and inserted a Neomycin (Neo)
resistance cassette under the control of a Herpes simplex
thymidine kinase promoter for the purposes of ES cell selection
[25]. It is now widely appreciated that the insertion of Neo genes
can have unintended consequences and reduce the expression of
nearby flanking genes and complicate or even confound our
understanding of gene function [29,30]. With the advent of Cre/
LoxP recombination, constructs can now be designed for the
elimination of Neo resistance genes. Given the importance of
PTPN2 in human disease and the complex phenotype in Ptpn2
2/2
(BALB/c-129SJ) mice, we used Cre/LoxP gene targeting to
generate Ptpn2 (C57BL/6) null mice without the Neo cassette and
compared the phenotype of these mice to that of Ptpn2
2/2
(BALB/c-129SJ) mice backcrossed onto the BALB/c versus
C57BL/6 backgrounds. Our results confirm and further char-
acterise the previously reported phenotype and identify strain-
dependent differences in bone development, thymocyte develop-
ment and myeloid hyperplasia and overall differences in morbidity
and mortality.
Results
Targeted disruption of Ptpn2
The Ptpn2 gene is located on chromosome 18 and has 7 exons
spread over approximately 60 kb of genomic DNA. To generate
a Ptpn2 null mouse using Cre/LoxP targeting, a construct was
designed with a PGK (Phosphoglycerate kinase)-Neo cassette
flanked with FRT recombination sites inserted downstream of
exon 2, and both exon 2 and PGK-neo flanked with LoxP
recombination sites for deletion using Cre recombinase; excision of
exon 2 would splice exon 1b to exon 3 to induce a frame-shift that
would result in early termination (TAA) and a putative 87 residue
protein (10,320 Da) incorporating 53 residues from the TCPTP
N-terminus (Fig. 1a). The linearised construct was electroporated
into C57BL/6 derived Bruce 4 embryonic stem (ES) cells.
Correctly targeted Neo resistant clones were injected into
blastocysts and high percentage chimeras crossed to C57BL/6J
Oz-Cre deleter mice (Ozgene) to excise exon 2 and the Neo
cassette (Fig. 1b) and thereon bred with C57BL/6J mice to
eliminate the Cre recombinase (Fig. 1c). The resulting Ptpn2
exon2-deleted mice (Ptpn2
ex2+/ex22) were maintained by breeding
heterozygotes (Fig. 1d). Ptpn2
ex22/ex22 were born at the expected
Mendelian frequency (Table S1). Western blot analyses using
antibodies (6F3) to the TCPTP non-catalytic C-terminus con-
firmed that full length TCPTP protein was not detectable in any of
the tissues examined in homozygous Ptpn2
ex22/ex22 mice (Fig. 1e).
The hypothetical 87 residue peptide resulting from the splicing of
exon 1b to 3 could not be detected with antibodies (6F7; raised
against the first 38 residues of TCPTP) to the TCPTP N-terminus
(Fig. 1f), consistent with the corresponding mRNA and/or
protein being unstable and the mice being null for TCPTP.
Morbidity and mortality in Ptpn2-deficient mice
At 2 weeks of age Ptpn2
ex22/ex22 (C57BL/6) mice were smaller
than their Ptpn2
ex2+/ex22 and wild type littermates, but otherwise
appeared and behaved normally. As reported previously for
Ptpn2
2/2 mice on the mixed BALB/c-129SJ background [25],
backcrossed (eight generations) Ptpn2
2/2 (BALB/c) mice were
runted and developed morbidity by 18–21 days of age,
characterized by a hunched posture, piloerection, eyelid closure,
decreased mobility and diarrhoea (Fig. 2; Table S2). The median
survival for Ptpn2
2/2 (BALB/c) was 21 days (Fig. 2b). In contrast,
the median survival for Ptpn2
ex22/ex22 mice was 32 days with some
mice surviving for almost 50 days (Fig. 2b). Notably at 29 days of
age Ptpn2
ex22/ex22 mice were runted, but behaved normally and
did not exhibit the overt signs of morbidity evident in Ptpn2
2/2
(BALB/c) mice (Table S2). To determine if these phenotypic
differences might be due to the respective BALB/c versus C57BL/
6 backgrounds, we backcrossed the Ptpn2
2/2(BALB/c) mice onto
the C57BL/6/J background strain for seven generations. We
found that the backcrossed Ptpn2
2/2 (C57BL/6/J) mice re-
sembled Ptpn2
ex22/ex22 mice in appearance and behaviour with
a median survival of 34 days (Fig. 2; Table S2; data not shown).
These results indicate that Ptpn2
ex22/ex22 mice phenocopy Ptpn2
2/
2 (C57BL/6) mice and that differences in morbidity and mortality
between Ptpn2
2/2 (BALB/c) and Ptpn2
ex22/ex22 mice might be
ascribed to differences in the background strain.
Bone development in Ptpn2-deficient mice
Previous studies have indicated that a bone marrow stromal cell
deficiency underlies the inflammatory phenotype and overt
Figure 1. Generation of Ptpn2
ex2+/ex22 mice. (a) Ptpn2 genomic locus and targeting design. (b–c) Southern blot analysis of Ptpn2
ex2+/ex2+ (+/+)
and Ptpn2
ex2+/ex22 (+/2) mice. (b) Exon (Ex) 2 floxed mice mated with Oz-Cre mice for the germline deletion of exon 2 and removal of the Neomycin
(Neo) resistance cassette. (c) Ex2-deleted mice were subsequently mated with C57BL/6 mice for the elimination of the Cre transgene. (d) PCR analysis
of Ptpn2
ex2+/ex2+ (+/+), Ptpn2
ex2+/ex22 (+/2) and Ptpn2
ex22/ex22 (2/2) mice. (e–f) Immunoblot analysis of TCPTP expression in lymphoid and non-
lymphoid tissues detected with antibodies to the TCPTP non-catalytic C-terminus (6F3) and TCPTP N-terminus (6F7; raised against the first 38 residues
of TCPTP); a non-specific (n.s.) protein detected by 6F7 is indicated. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0036703.g001
Ptpn2-Deficient Mice
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2/2 (BALB/c-129SJ) mice [25]. More recent
studies have shown that TCPTP deficiency in osteoblasts (C57BL/
6J-129SJ) increases osteoclast activity in vitro, without significantly
affecting the osteoblast or osteoclast number or bone formation/
volume in vivo [31]. We characterized the bones of Ptpn2
2/
2(BALB/c) and Ptpn2
ex22/ex22 mice to determine whether the
differences in morbidity might be associated with differences in
bone development. Hind legs were isolated from 14 day-old
Ptpn2
2/2 (BALB/c) and corresponding Ptpn2
+/2 and Ptpn2
+/+
littermates prior to the onset of overt morbidity [25,26], as well as
14 day-old Ptpn2
ex22/ex22 and Ptpn2
ex2+/ex2+ littermate mice. Legs
were fixed in 3.7% formaldehyde and processed for bone histology
and histomorphometric analysis as described previously [32]. 14
day-old Ptpn2
2/2 (BALB/c) mice had significantly smaller
skeletons, reflected in reduced femoral length and width, and
delayed development of the secondary ossification centre, in-
dicated by the high level of cartilage remaining in this zone (Fig 3).
In addition, in the proximal tibial metaphysis, a region of bone
remodeling, Ptpn2
2/2 (BALB/c) mice had increased trabecular
bone volume, characterized by high trabecular number (TbN) and
trabecular thickness (TbTh) and reduced trabecular separation
(TbSp) (Fig. 3; Table 1). A lower level of remodeling was
indicated by reduced osteoid deposition, and a significant re-
duction in osteoblast surface, along with a slight, but not
statistically significant reduction in osteoclast surface (Table 1).
Interestingly in 21 day-old Ptpn2
2/2 (BALB/c) mice, the delay in
the secondary ossification centre was no longer evident and the
increase in trabecular bone was less obvious (Fig. 3). In contrast to
Ptpn2
2/2 (BALB/c), we found slightly, but not significantly lower
femoral length in 14 day-old Ptpn2
ex22/ex22 mice, but no overt
difference in femoral width or trabecular bone volume (Fig. 3;
Table 2). Histological assessment indicated that Ptpn2
2/2
(C57BL/6) mice also did not exhibit any overt difference in size,
nor increased trabecular bone at 14 days of age (Fig. 3). At 21
days of age Ptpn2
ex22/ex22 bones were overtly smaller, and this was
associated with a striking reduction in the growth plate width;
again there was no increase in trabecular bone (Fig. 3). Taken
together, these results point towards TCPTP-deficiency resulting
in strain-dependent differences in bone development and remo-
deling.
Body composition in Ptpn2-deficient mice
Given the growth retardation, but discordant morbidity in
Ptpn2
2/2 (BALB/c) versus Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/
ex22 mice, we assessed the impact of TCPTP deficiency on body
composition by dual energy X-ray absorptiometry (DEXA) at 18
and 28 days as appropriate (Tables 3–4). Lean mass, fat mass and
bone mineral content and density were assessed in Ptpn2
ex22/ex22
and Ptpn2
2/2 (C57BL/6) mice and compared to that of Ptpn2
2/
2(BALB/c) mice and their corresponding heterozygous and/or
wild type littermates. Lean mass, fat mass and bone mineral
content but not bone mineral density, were reduced in Ptpn2
ex22/
ex22, Ptpn2
2/2 (C57BL/6) and Ptpn2
2/2(BALB/c) mice when
compared to their corresponding controls, consistent with the
Figure 2. Runtiness and mortality in Ptpn2
2/2 (BALB/c), Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice. (a) Images of representative 18
day-old Ptpn2
2/2 (BALB/c), 28 day-old Ptpn2
ex22/ex22 and 28 day-old Ptpn2
2/2 (C57BL/6) mice along with corresponding littermate wild type control
mice. (b) Kaplan-Meier survival curves for Ptpn2
2/2 (BALB/c), Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice. Statistical analyses were performed using
a Log Rank (Mantel-Cox) test with one degree of freedom.
doi:10.1371/journal.pone.0036703.g002
Ptpn2-Deficient Mice
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2/2 (BALB/c) mice. Representative longitudinal sections of tibiae from (a) 14 day-old Ptpn2
2/2 (BALB/c),
Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/ex22 mice, or (b) 21 day-old Ptpn2
2/2 (BALB/c) and Ptpn2
ex22/ex22 mice and their corresponding littermate wild
type controls stained with the von Kossa technique (mineralized bone stained black). In a) safranin O staining [only shown for 14 day-old Ptpn2
+/+
(BALB/c) and Ptpn2
2/2 (BALB/c)] highlights the delayed cartilage (in orange) destruction; scale bar=100 micron.
doi:10.1371/journal.pone.0036703.g003
Table 1. Bone histomorphometry in Ptpn2
2/2 (BALB/c) mice.
Ptpn2
+/+ (n=8) Ptpn2
+/2 (n=4) Ptpn2
2/2 (n=10) p value +/+ v/s 2/2
Femoral length (mm) 6 SE 9.560.3 9.260.2 7.860.2 0.002
Femoral width (mm) 6 SE 0.9360.01 0.9260.04 0.8360.01 0.002
Trabecular bone volume BV/TV (%) 6 SE 4.860.6 4.260.1 8.961.0 0.006
Trabecular number TbN (mm) 6 SE 2.460.2 2.360.4 3.960.4 0.006
Trabecular thickness TbTh (mm) 6 SE 19.560.8 17.461.7 23.061.1 0.027
Trabecular separation TbSp (mm) 6 SE 411629 462699 262630 0.006
Osteoid volume OV/BV (%) 6 SE 5.261.1 5.061.0 2.060.5 0.02
Osteoid surface OS/BS (%) 6 SE 18.462.7 18.263.7 12.363.0 0.17
Osteoid thickness (mm) 6 SE 2.660.2 2.460.1 1.960.1 0.004
Osteoblast surface ObS/BS (%) 6 SE 29.763.9 27.666.1 17.664.0 0.04
Osteoclast surface OcS/BS (%) 6 SE 21.462.5 28.366.6 15.362. 5 0.08
Number of Osteblasts/Bone perimeter Nob/BPm (/mm) 6 SE 18.762.0 11.064.0 12.062.6 0.09
Number of Osteclasts/Bone perimeter Noc/BPm (/mm) 6 SE 5.660.8 8.562. 6 4.160.6 0.10
Bone volume/Trabecular bone volume (BV/TV), trabecular number (TbN), trabecular thickness (TbTh) and trabecular separation (TbSp) in 14 day-old Ptpn2
+/+ (BALB/c),
Ptpn2
+/2 (BALB/c) and Ptpn2
2/2 (BALB/c) mice. Osteoid surface/bone surface (OS/BS), osteoid thickness, osteoid volume/bone volume (OV/BV), osteoblast surface/bone
surface (ObS/BS), osteoclast surface/bone surface (OcS/BS), number of osteoblasts/bone perimeter (Nob/BPm) and number of osteoclasts/bone perimeter (Noc/BPm)
are also shown. Results shown are means 6 SEM; p values are for Ptpn2
+/+ versus Ptpn2
2/2 mice and were determined using a two-tailed Mann-Whitney U Test.
doi:10.1371/journal.pone.0036703.t001
Ptpn2-Deficient Mice
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normalized to total body weight were unaltered in Ptpn2
ex22/ex22,
Ptpn2
2/2 (C57BL/6) and Ptpn2
2/2(BALB/c) mice when com-
pared to controls, in line with the mice being proportionately
smaller and the difference in growth being developmental in
nature. Relative fat masses were decreased in Ptpn2
ex22/ex22,
Ptpn2
2/2 (C57BL/6) and Ptpn2
2/2(BALB/c) mice when com-
pared to controls, consistent with TCPTP deficiency affecting
energy balance, whereas bone mineral densities normalized to
body weight were increased (Tables 3–4); at 18 days of age the
increase in bone mineral density was greatest in Ptpn2
2/2 (BALB/
c) mice consistent with the strain-dependent differences in bone
development as revealed by histology and histomorphometry
(Fig. 3; Table 1). Overall there were no overt differences in body
composition between Ptpn2
ex22/ex22, Ptpn2
2/2 (C57BL/6) and
Ptpn2
2/2(BALB/c) mice, consistent with the strain-dependent
differences in morbidity and mortality being independent of gross
body composition.
T cell development in Ptpn2-deficient mice
T cell progenitor cells arise in the bone marrow and enter the
thymus to form double negative (DN) cells that lack surface CD4
and CD8 and undergo maturation to develop into double positive
(DP) thymocytes (CD4
+CD8
+) that express CD4 and CD8. DP
thymocytes that are positively and negatively selected form single
positive (SP) thymocytes [CD4
+CD8
2, CD4
2CD8
+] that ulti-
mately leave the thymus as CD4
+ and CD8
+ naı ¨ve T cells [33].
We compared thymocyte development in 18 day-old Ptpn2
2/2
(BALB/c) versus Ptpn2
ex22/ex22 mice and their corresponding
littermates (Fig. 4). 18 day-old Ptpn2
2/2 (BALB/c) mice exhibited
overt thymic atrophy associated with a 4–5 fold decrease in total
cellularity; DN, DP and SP thymocytes (Fig. 4a), in particular in
the CD4
+CD8
2 lineage, were decreased as reported previously for
Ptpn2
2/2 (BALB/c-129SJ) mice [25]. In contrast thymic atrophy
was not evident in Ptpn2
ex22/ex22 mice and total and DP
thymocytes were decreased by only 50%, whereas SP thymocytes
remained unaltered; thymic atrophy was also not evident in 18
day-old Ptpn2
2/2 (C57BL/6) mice (data not shown). Interestingly,
SP/DP ratios (in particular CD4
28
+/DP ratios) were significantly
increased in both Ptpn2
2/2 (BALB/c) and Ptpn2
ex22/ex22 18 day-
old mice (Fig. 4a). The enhanced SP/DP ratios suggested that
TCPTP-deficiency altered thymocyte development. One possibil-
ity is that thymocyte negative selection might be defective in
TCPTP-deficient mice and thus contribute to enhanced SP
generation. However, negative selection as monitored by the
deletion of Vb5+ and Vb3+ TCR SPs by the endogenous MMTV
(mouse mammary tumour provirus) 6 and 8 superantigens in 14–
16 day-old Ptpn2
2/2 (BALB/c) mice was not diminished, but
rather modestly enhanced (Fig. 4b). Another possibility is that
positive selection might be enhanced. Thymocyte positive selection
can be minimally subdivided into four progressive stages based on
changes in the expression of TCRb and CD69 [34]. Pre-selection
Table 2. Bone histomorphometry in Ptpn2
ex22/ex22 (C57BL/6) mice.
Ptpn2
ex2+/ex2+ (n=7–8) Ptpn2
ex22/ex22 (n=7–8) p value +/+ v/s 2/2
Femoral length (mm) 6 SE 8.660.1 8.060.3 0.097
Femoral width (mm) 6 SE 1.0460.03 1.0460.03 1.000
Trabecular bone volume BV/TV (%) 6 SE 2.9560.70 3.6860.41 0.382
Trabecular number TbN (mm) 6 SE 1.4660.32 1.6760.19 0.645
Trabecular thickness TbTh (mm) 6 SE 20.060.8 22.761.7 0.130
Trabecular separation TbSp (mm) 6 SE 12536495 646.9693 0.645
Bone volume/Trabecular bone volume (BV/TV), trabecular number (TbN), trabecular thickness (TbTh) and trabecular separation (TbSp) in 14 day-old Ptpn2
ex2+/ex2+
(C57BL/6) and Ptpn2
ex22/ex22 (C57BL/6) mice. Results shown are means 6 SEM; p values are for Ptpn2
+/+ versus Ptpn2
2/2 mice and were determined using a two-tailed
Mann-Whitney U Test.
doi:10.1371/journal.pone.0036703.t002
Table 3. Body composition in 18 day-old Ptpn2
2/2 (BALB/c), Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice.
Ptpn2 (BALB/c) Ptpn2
ex2/ex2 Ptpn2 (C57BL/6)
Age 18 d +/+ (n=13) 2/2 (n=5) p-value +/+ (n=10) 2/2 (n=8) p-value +/+ (n=9) 2/2 (n=8) p-value
Lean Mass (g) 6SE 8.760.4 4.760.6 0.002 6.860.3 5.160.6 0.03 9.460.8 6.060.6 0.01
Lean Mass/Body Weight (%) 6SE 74.061.1 84.062.4 0.003 77.060.5 81.061.8 0.13 80.060.7 82.063.8 0.69
Fat Mass (g) 6SE 3.260.3 0.960.1 0.002 2.160.1 1.260.2 0.01 2.460.2 1.360.3 0.01
Fat Mass/Body Weight (%) 6SE 26.261.1 16.562.3 0.006 23.260.6 18.561.9 0.16 19.960.7 18.363.8 0.69
BMC (g) 6SE 0.0760.01 0.0360.01 0.06 0.0460.01 0.0360.01 0.42 0.1060.02 0.0560.01 0.04
BMC/Body Weight (%) 6SE 0.5460.09 0.5360.21 1.00 0.4260.05 0.4860.06 0.41 0.8060.09 0.6060.11 1.00
BMD 6SE [BMC(g)/Area (cm
2)] 0.03060.001 0.02660.002 0.18 0.03060.001 0.02560.001 0.67 0.03060.001 0.02760.001 0.09
BMD/Body Weight (%) 0.2560.01 0.5060.09 0.006 0.2960.01 0.4260.04 0.0004 0.2760.02 0.4060.04 0.01
Body composition [lean, fat, bone mineral content (BMC) and bone mineral density (BMD)] in Ptpn2
2/2 (BALB/c), Ptpn2
ex22/ex22 (C57BL/6) and Ptpn2
2/2 (C57BL/6) mice
and in the corresponding wild type littermates measured by DEXA and normalised to total body weight. Results shown are means 6 SEM; p values are for Ptpn2
+/+
versus Ptpn2
2/2 mice and were determined using a two-tailed Mann-Whitney U Test.
doi:10.1371/journal.pone.0036703.t003
Ptpn2-Deficient Mice
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loCD69
lo (stage 1), DPs initiating
positive selection are TCRb
intCD69
int/hi (stage 2), whereas
thymocytes in the process of positive selection are TCRb
hiCD69
hi
(stage 3) and SPs that have completed positive selection are
TCRb
hiCD69
lo (stage 4) [34]. We noted increases in the number
of Ptpn2
2/2 (BALB/c) thymocytes initiating, undergoing and
completing positive selection (Fig. 4c). Even greater increases in
thymocytes initiating and completing positive selection were noted
in 18 day-old Ptpn2
ex22/ex22 mice (Fig. 4c). Taken together, these
results are consistent with TCPTP deficiency enhancing both
negative and positive selection. Nonetheless, in keeping with the
effects on thymic cellularity, we found that peripheral lymph node
CD4+ and CD8+ T cells were reduced in Ptpn2
2/2 (BALB/c)
mice and increased in Ptpn2
ex22/ex22 mice (Fig. 5). Given the
differences in thymic atrophy/cellularity in 18 day-old Ptpn2
2/2
(BALB/c) versus Ptpn2
ex22/ex22 mice, we also monitored thymo-
cyte subsets in 28–29 day-old Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/
ex22 mice. Thymic atrophy was evident in both 28 day-old Ptpn2
2/
2 (C57BL/6) and 29 day-old Ptpn2
ex22/ex22 mice and coincided
with profound decreases in total, DN, DP and SP thymic
cellularity, as seen in 18 day Ptpn2
2/2 (BALB/c) mice (Fig. 6).
These results point towards both age- and strain-dependent
differences in thymic atrophy versus thymocyte development and
suggest that the overt thymic atrophy may be a consequence of
extrinsic influences.
Splenomegaly and lymphadenopathy in Ptpn2-deficient
mice
In addition to thymic atrophy Ptpn2
2/2 (BALB/c-129SJ) mice
develop splenomegaly after two weeks of age [25]. Splenomegaly
was evident in 18 day-old Ptpn2
2/2(BALB/c) mice (Fig. 7a),
albeit not as pronounced as that reported previously for Ptpn2
2/2
(BALB/c-129SJ) mice [25]. In contrast, spleen weights were not
significantly altered in 28 day-old Ptpn2
2/2 (C57BL/6) or
Ptpn2
ex22/ex22 mice (Fig. 7a). Splenomegaly in Ptpn2
2/2
(BALB/c-129SJ) mice has been associated with an increase in
the red pulp and an accumulation of myeloid cells [25]. We found
that total CD11b
+ and CD11b
+Gr
+ (but not CD11b
+Gr
2) myeloid
cells were increased dramatically in the spleens of Ptpn2
2/2
(BALB/c) mice, but not in Ptpn2
2/2 (C57BL/6), or Ptpn2
ex22/ex22
(C57BL/6) mice when compared to their corresponding litter-
mates (Fig. 7b). On the other hand CD11b
+ cells were decreased
in the bone marrow of Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/ex22
mice, consistent with a defect in myeloid development, however
this was not evident in Ptpn2
2/2 (BALB/c) mice (Fig. 7c). Ptpn2
2/
2 (BALB/c), Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/ex22 mice had
decreased bone marrow cellularity (Fig. 7c), in keeping with their
smaller bones and increased relative bone mineral density
(Tables 1–2).
Lymphadenopathy and increases in lymph node (LN) cellula-
rities have also been reported for Ptpn2
2/2 (BALB/c-129SJ) mice
[25]. Lymphodenopathy was not evident in Ptpn2
2/2 (BALB/c)
mice (Fig. 7d), rather, LN weights (normalised to total body
weight) were unaltered and cellularity reduced (,5 fold) in
Ptpn2
2/2 (BALB/c) mice. On the other hand, LN weights were
modestly increased in Ptpn2
ex22/ex22 mice and LN weights trended
higher in Ptpn2
2/2 (C57BL/6) mice, whereas cellularity (4–
15 mm; Z2 coulter counter) was unaltered in Ptpn2
ex22/ex22 mice
and decreased (,2.9 fold) in Ptpn2
2/2 (C57BL/6) mice (Fig. 7d).
These results indicate that the effects of TCPTP deficiency on
splenomegaly, myeloid development and lymphodenopathy are
strain-dependent.
B cell development in Ptpn2-deficient mice
We next assessed B cell development in 18 day-old Ptpn2
2/2
(BALB/c), 28 day-old Ptpn2
2/2 (C57BL/6) and 29 day-old
Ptpn2
ex22/ex22 mice (versus corresponding littermates). B cells
originate from precursors in the bone marrow and undergo
sequential maturation and V(D)J recombination developing into
immature B cells that express B cell receptor and membrane-
bound IgM [35]. Immature B cells emigrate to the spleen where
they mature further into three broad populations according to
anatomical localization, phenotypic characterization and function:
follicular B cells (IgM
loIgD
hiB220
hi), marginal zone B cells
(IgM
hiIgD
lo B220
hi) and B-1 cells (IgM
hiIgD
lo B220
lo) [35].
Previous studies have shown that B cell intrinsic defects and bone
marrow stromal abnormalities in TCPTP-deficient mice lead to an
early block in B cell development [25,28]. Consistent with this we
found a dramatic reduction in total B220
+ B cells, IgM
2IgD
2-
B220
lo progenitor B cells, IgM
hiIgD
loB220
lo immature B cells and
IgM
intIgD
hiB220
hi mature recirculating B cells in bone marrow
and decreased splenic marginal zone B cells, follicular B cells and
B-1 cells (Fig. 8a–b). Although bone marrow B cell development
was perturbed in all three mouse lines, the impact of TCPTP
deficiency on the development of splenic B cells was most dramatic
in Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/ex22 mice (Fig. 8b).
Table 4. Body composition in 28 day-old Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice.
Ptpn2
ex2/ex2 Ptpn2 (C57BL/6)
+/+ (n=10) 2/2 (n=8) p value +/+ (n=9) 2/2 (n=8) p value
Lean Mass (g) 6SE 13.860.7 5.760.5 0.0001 14.761.0 6.660.5 0.0003
Lean Mass/Body Weight (%) 6SE 81.060.7 86.060.8 0.0004 85.060.7 87.061.0 0.09
Fat Mass (g) 6SE 3.360.2 0.960.1 0.0001 2.760.3 0.960.1 0.0003
Fat Mass/Body Weight (%) 6SE 19.360.7 13.460.7 0.0001 15.260.7 13.161.2 0.18
BMC (g) 6SE 0.1960.01 0.0560.01 0.0001 0.2360.02 0.0860.01 0.0006
BMC/Body Weight (%) 6SE 1.0960.03 0.7060.13 0.06 1.2960.07 1.0260.13 0.09
BMD 6SE [BMC(g)/Area (cm
2)] 0.03760.001 0.02560.001 0.0001 0.04160.002 0.02860.001 0.0006
BMD/Body Weight (%) 0.2260.01 0.4060.04 0.0001 0.2460.01 0.3860.01 0.0006
Body composition [lean, fat, bone mineral content (BMC) and bone mineral density (BMD)] in 28 day-old Ptpn2
ex22/ex22 (C57BL/6) and Ptpn2
2/2 (C57BL/6) mice and in
the corresponding wild type littermates measured by DEXA and normalised to total body weight. Results shown are means 6 SEM; p values are for Ptpn2
+/+ versus
Ptpn2
2/2 mice and were determined using a two-tailed Mann-Whitney U Test.
doi:10.1371/journal.pone.0036703.t004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36703Figure 4. Thymocyte development in 18 day-old Ptpn2
2/2 (BALB/c) and Ptpn2
ex22/ex22 mice. (a) Thymi from the indicated 18 day-old
littermates were weighed using an analytical balance and normalised to body weight. Thymocytes were stained with fluorochrome-conjugated
antibodies against CD4 and CD8 and analyzed by flow cytometry. Cells were gated for the DP, SP and DN stages and absolute numbers and the
indicated ratios determined. (b) Thymocytes from Ptpn2
+/+ and Ptpn2
2/2 (BALB/c) littermates were stained with fluorochrome-conjugated antibodies
against CD4, CD8, TCR-Vb3, -5, -6 and -8 and analyzed by flow cytometry. Cells were gated for the CD4 and CD8 SP stages and the percentages of
Ptpn2-Deficient Mice
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36703Conversely, LN B cell subsets were most dramatically altered in
Ptpn2
2/2 (BALB/c), with no overt differences seen in Ptpn2
ex22/
ex22 mice (Fig. 8c).
Erythropoiesis in Ptpn2-deficient mice
Ptpn2
2/2 (BALB/c-129SJ) mice develop severe anemia by 21
days of age associated with defective bone marrow erythropoiesis
[25]. Erythropoiesis is a dynamic process that involves multiple
differentiation steps and progression from early progenitor cells to
enucleated red blood cells. Pluripotent hematopoietic stem cells
and multipotent progenitor cells in the bone marrow give rise to
committed erythroid precursors, which sequentially develop into
mature erythrocytes [36]. We found that CD117
+Ter119
2
progenitor cells and CD117
2Ter119
+ erythroid cells (early pro-
erythroblast to mature erythrocyte) were decreased by more than
80% in Ptpn2
2/2 (BALB/c), Ptpn2
2/2 (C57BL/6) and Ptpn2
ex22/
ex22 mice when compared to their corresponding littermates
(Fig. 9a). Circulating erythrocytes were also reduced, but this was
most dramatic in Ptpn2
2/2 (BALB/c) mice (Fig. 9b). Interesting-
ly, the decrease in erythroid cells was greater than the decrease in
erythrocytes (Fig. 9), consistent with tissues such as the spleen and
liver compensating for the defective bone marrow erythropoiesis.
These results indicate that erythroid development is defective in
TCPTP-deficient mice.
Discussion
In this study we have generated mice that are globally deficient
for the tyrosine phosphatase TCPTP using Cre/LoxP recombi-
nation to remove both Ptpn2 exon 2 and the Neomycin resistance
cassette used for ES cell selection. The phenotype of these mice
reaffirms that reported previously for mice generated by
homologous recombination, where the Neo cassette was left in
place [25]. Thus, our studies indicate that the morbidity and
mortality and the perturbations in hematopoiesis and erythropoi-
esis in Ptpn2
2/2 (BALB/c) can be ascribed to a deficiency in
TCPTP, rather than extrinsic influences that may arise from the
presence of the Neo resistance gene. Furthermore, our studies
define strain-dependent differences in morbidity and mortality and
differences in thymocyte, myeloid and bone development.
Global TCPTP-deficiency was associated with differences in
morbidity and mortality on the BALB/c versus C57BL/6
background strains. The outward signs of morbidity in Ptpn2
2/2
(BALB/c) mice, including hunched posture, piloerection, de-
creased mobility, eyelid closure and diarrhoea were not evident in
the corresponding mice on the C57BL/6 background. Moreover,
lifespan was prolonged in TCPTP-deficient on the C57BL/6
background. The underlying reason(s) for the strain-dependent
differences in morbidity and mortality is/are not clear. One
TCR-Vb3, -5, -6 and -8 T cells determined. (c) Thymocytes from the indicated 18 day-old mice were stained with fluorochrome-conjugated antibodies
against CD4, CD8, TCRb and CD69 and analyzed by flow cytometry. Cells were gated for the different developmental stages according to the
expression of the positive selection markers TCRb and CD69. Results in (a–c) are means 6 SEM for the indicated number of mice and are
representative of at least two independent experiments; significance determined using a two-tailed Mann-Whitney U Test; *p,0.05 ** p,0.01 ***
p,0.001.
doi:10.1371/journal.pone.0036703.g004
Figure 5. Peripheral T cells in Ptpn2-deficient mice. (a) Splenocytes or peripheral lymph node cells from 18 day-old Ptpn2
2/2 (BALB/c) mice, 18
day-old Ptpn2
ex22/ex22 mice and their corresponding littermates were stained with fluorochrome-conjugated antibodies against CD4, CD8 and TCRb
and analysed by flow cytometry and absolute numbers determined. (b) Splenocytes or peripheral lymph node cells from 28 day-old Ptpn2
ex22/ex22
mice, 29 day-old Ptpn2
2/2 (C57BL/6) mice and their corresponding littermates were stained with fluorochrome-conjugated antibodies against CD4,
CD8 and TCRb and analysed by flow cytometry and absolute numbers determined. Results shown in (a–b) are means 6 SEM for the indicated
number of mice and are representative of at least two independent experiments; significance determined using a two-tailed Mann-Whitney U Test;
*p,0.05 ** p,0.01 *** p,0.001.
doi:10.1371/journal.pone.0036703.g005
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Although growth retardation and defects in lymphocyte and
erythroid development were evident irrespective of the back-
ground strain, the impact on the myeloid compartment was
distinct. Despite bone marrow cellularity being decreased in both
28 day-old C57BL/6 and 18 day-old BALB/c strain TCPTP-
deficient mice (in line with their smaller size), only C57BL/6
TCPTP-deficient mice exhibited a corresponding decrease in bone
marrow CD11b
+ cells. Thus, monocytic/granulocytic develop-
ment may be increased in Ptpn2
2/2 (BALB/c) mice. This was
accompanied by a dramatic increase in CD11b
+Gr1
+, but not
CD11b
+Gr1
2 cells in the spleens of Ptpn2
2/2 (BALB/c) mice. The
anti-granulocyte receptor 1 (Gr1) antibody RB6-8C5 binds to
Ly6G on the surface of granulocytes and Ly6C present on both
granulocytes and monocytes/macrophages and some lympho-
cytes. Two major monocytic subsets exist in the periphery, the
‘inflammatory’ and ‘circulating’ monocytes [37]. Inflammatory
monocytes express Ly6C (Gr1
+) and migrate to the spleen and
inflamed tissues, where they become macrophages, whereas
circulating monocytes are Gr1
2 and serve to replenish resident
tissue macrophages. The dramatic increase in granulocytes and/or
inflammatory macrophages in the spleens of Ptpn2
2/2 (BALB/c)
mice is consistent with inflammation and previous studies
establishing the development of progressive systemic inflammatory
disease in Ptpn2
2/2 (BALB/c-129SJ) mice [25].
Our studies also define strain-dependent differences in thymic
atrophy and thymocyte development that might contribute to the
differences in morbidity in BALB/c versus C57BL/6 strain
TCPTP-deficient mice. In particular, thymic atrophy and the
overt decrease in thymic cellularity were evident sooner in the
Ptpn2
2/2 (BALB/c) mice. The reasons for the strain-dependent
temporal differences in thymic atrophy are not clear. The decrease
in thymocyte cellularity in BALB/c and C57BL/6 strain TCPTP-
deficient mice might be attributable at least in part to the non-
specific depletion of DP thymocytes by inflammatory cytokines
such as TNF and IFNc that are increased in Ptpn2
2/2 (BALB/c-
129SJ) mice [26] and have been linked previously with the
induction of DP apoptosis in vivo [38]. However, this might also be
a consequence of defective lymphoid progenitor development in
the bone marrow. In future studies it will be important to
determine whether there are strain-dependent differences in
inflammation and lymphoid progenitor development in Ptpn2
2/
2 mice. Nevertheless, despite the decreased cellularity, we found
that TCPTP-deficiency enhanced both positive and negative
selection and overall resulted in increased SP/DP ratios. The
enhanced positive selection was evident in particular in young
Ptpn2
ex22/ex22 and reflected by an increase in peripheral T cell
numbers. These results are consistent with our recent analyses of
thymocyte/T cell-specific TCPTP-deficient (Lck-Cre;Ptpn2
lox/lox)
mice, where positive selection and SP/DP ratios are also increased
[39]. Although T cell-specific TCPTP deficiency results in
inflammation and autoimmunity in aged mice [24], it is possible
that the enhanced T cell numbers in young Ptpn2
ex22/ex22 might
be beneficial.
Phenotypic differences in different strains of mice carrying
targeted null mutations have been reported previously and linked
with the existence of second-site modifier genes that affect
penetrance [40,41,42,43,44]. In particular, mice lacking the
retinoblastoma (Rb)-related p107 gene develop growth deficiency
on the BALB/c, but not C57BL/6 background strains [40].
Indeed, the overall phenotype of p107
2/2 (BALB/c) mice is highly
reminiscent of that seen in Ptpn2
2/2 (BALB/c) mice. In addition
to postnatal growth retardation, p107
2/2 (BALB/c) mice have
a higher incidence of morbidity and exhibit myeloid hyperplasia
[40] and a suppression of B-lymphopoiesis and erythropoiesis [45].
The myeloid hyperplasia in p130-deficient mice is linked with
perturbations in the bone marrow microenvironment [45].
Ptpn2
2/2 (BALB/c-129SJ) mice also exhibit bone marrow stromal
cell defects associated with increased INFc production [26,28].
The defect(s) in the bone marrow microenvironment in Ptpn2
2/2
Figure 6. Thymoycte development in 28 day-old Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice. Thymi from the indicated littermate mice
were weighed using an analytical balance and normalised to body weight. Thymocytes were stained with fluorochrome-conjugated antibodies
against CD4 and CD8 and analyzed by flow cytometry. Cells were gated for the DP, SP and DN stages and absolute numbers and the indicated ratios
determined. Results shown are means 6 SEM for the indicated number of mice and are representative of at least two independent experiments;
significance determined using a two-tailed Mann-Whitney U Test; *p,0.05 *** p,0.001.
doi:10.1371/journal.pone.0036703.g006
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has/have been shown to be responsible for the block in B cell
development [25,28]. Although we did not assess if TCPTP-
deficiency results in strain-dependent differences in the bone
marrow stroma, we did observe a striking difference in bone
development in Ptpn2
2/2 (BALB/c) versus Ptpn2
ex22/ex22 mice.
At 14 days of age Ptpn2
2/2 (BALB/c) mice had smaller
skeletons due to a delay in bone development, as reflected by the
large volume of unresorbed cartilage in the secondary ossification
centre (at the epiphysis). Moreover, we found that trabecular bone
was increased significantly in Ptpn2
2/2 (BALB/c) mice, compris-
ing mainly of woven bone rather than more mature lamellar bone,
consistent with the developmental delay. Our findings are
consistent with global TCPTP deficiency delaying bone de-
velopment and decreasing bone turnover on the BALB/c
background. Interestingly, in 21 day-old Ptpn2
2/2 (BALB/c) mice
the delay in the secondary ossification was no longer evident and
only modest effects on trabecular bone were seen. Therefore, these
results are not inconsistent with a recent study that has reported
that 21 day-old Ptpn2
2/2 (BALB/c) mice exhibit spontaneous
synovitis associated with synovial inflammation and increased
osteoclast density and decreased rather than increased bone
volume [46]. The overt differences we observed in bone
development in Ptpn2
2/2 (BALB/c) mice were not present in
Ptpn2
ex22/ex22 mice at 14 days of age. Moreover in contrast to 21
day-old Ptpn2
2/2 (BALB/c) mice, TCPTP deficiency on the
Figure 7. Splenomegaly, myeloid development and lymphadenopathy in Ptpn2-deficient mice. (a) Spleen weights from 18 day-old
Ptpn2
2/2 (BALB/c) and 28 day-old Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice and corresponding wild type littermate mice. (b) Splenocytes or (c)
bone marrow (tibia and femur) cells were stained with fluorochrome-conjugated antibodies to CD11b and Gr1 and analysed by flow cytometry;
absolute numbers of CD11b
+, CD11b
+Gr1
+ and CD11b
+Gr1
2 were determined (d) Weights of pooled peripheral lymph nodes from 18 day-old
Ptpn2
2/2 (BALB/c) and 28 day-old Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice and corresponding wild type littermate mice. Results shown in (a–d)
are means 6 SEM for the indicated number of mice and are representative of at least two independent experiments; significance determined using
a two-tailed Mann-Whitney U Test; *p,0.05 ** p,0.01 *** p,0.001.
doi:10.1371/journal.pone.0036703.g007
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growth plate at 21 days of age; an influence that would cause
a slowing of longitudinal growth and might therefore be
responsible for the smaller skeletons in these mice. Therefore,
although TCPTP-deficiency results in smaller skeletons irrespec-
tive of strain by 21 days of age, the underlying causes might be
different and strain-dependent. A similar growth plate phenotype
to that of the Ptpn2
ex22/ex22 mice has been noted previously in
growth hormone (GH) receptor deficient mice [47]. Interestingly,
mice that lack TCPTP specifically in neuronal cells (Nes-
Cre;Ptpn2
lox/lox) are also runted and this is associated with
decreased circulating GH, which, amongst other influences, affects
post-natal growth [39].
It is well established that the bone microenvironment plays
a central role in hematopoietic stem cell fate [48,49]. Further
studies should focus on delineating the precise cellular and
molecular mechanisms that underlie the strain-dependent differ-
ences in bone development and potentially bone marrow stroma
in Ptpn2
2/2 mice and the relative contributions of bone to the
perturbations in hematopoiesis and erythropoiesis and the
morbidity and mortality that are associated with global TCPTP-
deficiency.
Methods
Ethics statement
All experiments were performed in accordance with the
NHMRC Australian Code of Practice for the Care and Use of
Animals and approved by the Monash University School of
Biomedical Sciences Animal Ethics Committee (Ethics number
SOBSB/B/2008/53).
Figure 8. B cell development in Ptpn2-deficient mice. Bone marrow cells (pooled from one tibia and one femur), splenocytes or pooled
peripheral lymph node cells from 18 day-old Ptpn2
2/2 (BALB/c), 28 day-old Ptpn2
ex22/ex22 and 29 day-old Ptpn2
2/2 (C57BL/6) mice and their
corresponding littermates (a–c) were stained with fluorochrome-conjugated antibodies to CD45R(B220), IgM and IgD and analysed by flow
cytometry. Absolute numbers of progenitor (B220
loIgM
loIgD
lo), immature (B220
loIgM
hi IgD
lo), mature (B220
hiIgM
intIgD
hi) B cells and B1 (B220
lo
IgM
hiIgD
lo), follicular (B220
hiIgM
loIgD
hi) and marginal zone (B220
hiIgM
hiIgD
lo) B cells were determined. Results shown are means 6 SEM for the
indicated number; significance determined using a two-tailed Mann-Whitney U Test; *p,0.05 ** p,0.01 *** p,0.001.
doi:10.1371/journal.pone.0036703.g008
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Mouse anti-actin from Thermo Scientific (Fremont, CA), anti-
tubulin (Ab-5) from Sigma-Aldrich (St Louis, MO) and anti-
TCPTP (6F3, 6F7) from Medimabs (Quebec, Canada). The
following fluorochrome-conjugated antibodies for flow cytometry
from BD Biosciences (San Jose, CA) were used for staining:
fluorescein isothiocyanate (FITC)-conjugated anti-mouse
CD45R(B220) (RA3-6B2), FITC-conjugated anti-TCR-Vb3
(KJ25), FITC-conjugated anti-TCR-Vb5.1/5.2 (MR9-4), FITC-
conjugated anti-TCR-Vb6 (RR4-7), FITC-conjugated anti-TCR-
Vb8.1-8.2 (MR5-2), FITC-conjugated anti-TCRb (H57-597),
FITC-conjugated anti-CD117 (2B8), phycoerythrin (PE)-cyanine
7-conjugated anti-CD4 (RM4-5), PE-cyanine dye7-conjugated
anti-CD69 (H1.2F3), PE-cyanine dye7-conjugated anti-IgM (R6-
60.2), PE-conjugated anti-IgD (11–26), PE-conjugated anti-
Ter119 (Ly-76), PE-conjugated anti-Ly6G and Ly6C (Gr1)
(RB6-8C5), Alexa 647 (A647)-conjugated anti-CD8 (53-6.7).
Mice
We maintained mice on a 12 h light-dark cycle in a tempera-
ture-controlled high barrier facility (Monash University ARL) with
free access to food and water. Ptpn2
2/2 mice on a 129sv6BALB/c
mixed background have been described previously [25] and were
backcrossed onto a BALB/c background for eight generations.
Ptpn2
2/2 (BALB/c) were backcrossed onto a C57BL/6 back-
ground for seven generations. Ptpn2
2/2 (BALB/c) and Ptpn2
2/2
(C57BL/6) mice were genotyped as described previously [25].
Littermates and aged-matched mice from heterozygous breeding
pairs were used in all experiments.
Generation and genotyping of Ptpn2
ex22/ex22 Mice
Ptpn2
ex2+/ex22 mice were generated by Ozgene (Perth, Austra-
lia). The targeting construct was produced using C57BL/6
genomic DNA and the Ozgene PelleNeo vector and incorporated
LoxP sites flanking both exon (Ex) 2 and a PGK-Neo-selection
cassette flanked by FRT sites inserted downstream of exon 2
(Fig. 1). The linearised construct was electroporated into Bruce 4
(C57BL/6J) ES cells and correctly targeted G418 resistant clones
identified by Southern blotting and injected into blastocysts for the
generation of male chimeras that were mated with C57BL/6J
mice to produce Ptpn2
ex2+/ex22 offspring. Deletion of exon 2 and
removal of the Neo cassette were achieved by crossing with Oz-
Cre deleter mice (Ozgene) and the resulting progeny bred with
C57BL/6 mice for the elimination of the Cre transgene; deletion
of exon 2, removal of Neo and the elimination of Cre were
monitored by Southern blotting. Ptpn2
ex2+/ex22 mice were
genotyped by PCR: forward primer P1 59TGCAGT-
TATGGTTTTCCTCAGTCCC39 and reverse primer P2:
59ACAGT GCTGGTTGCTGTTTAGCCTC39.
Flow cytometry
Freshly isolated thymi, spleens and peripheral lymph nodes
were homogenized by gently compressing them between two
frosted glass slides or with the sterile end of a plunger and washed
with ice-cold PBS supplemented with 2% (v/v) fetal bovine serum
(FBS; CSL, Australia); cell suspensions were resuspended further
with an 18G needle. Bone marrow was isolated by flushing tibias
and femurs with ice cold PBS supplemented with 0.2% BSA with
a 26G needle. The resulting marrow was then gently resuspended
using a 22G needle. Cell suspensions were recovered by
centrifugation (3006 g, 5 min at 4uC), red blood cells removed
Figure 9. Erythrocyte development in Ptpn2-deficient mice. (a) Bone marrow cells (pooled from one tibia and one femur) from 18 day-old
Ptpn2
2/2 (BALB/c) and 28 day-old Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice and corresponding littermate wild type control mice were stained
with fluorochrome-conjugated antibodies to CD117 and Ter119 and analysed by flow cytometry. Absolute numbers of progenitor (CD117
+ Ter119
2)
and erythroid (CD117
2Ter119
+) cells were determined. (b) Red blood cells were quantified (identified in the forward and side scatter according to size
and granularity) by flow cytometry. Results shown are means 6 SEM for the indicated number of mice and are representative of two independent
experiments; significance determined using a two-tailed Mann-Whitney U Test; *p,0.05 ** p,0.01 *** p,0.001.
doi:10.1371/journal.pone.0036703.g009
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and cell counts (4–15 mm) determined with a Z2 Coulter Counter
(Beckman Coulter, Fullerton, CA). For cell surface staining, 3610
6
lymphocytes were resuspended in PBS/2% FBS containing the
fluorochrome-conjugated antibodies and incubated on ice for
20 min. Cells were washed once in PBS/2% FBS to remove
unbound antibodies and analyzed on a LSRII flow cytometer (BD
Biosciences, San Jose, CA). For the quantification of red blood
cells, mice were bled and a known number of Calibrite
TM Beads
(BD Biosciences, San Jose, CA) added to a defined volume of
diluted blood and analysed by flow cytometry (LSRII). Red blood
cells were identified in the forward and side scatter according to
their size. Data was analyzed using FACSDiVa (BD Biosciences,
San Jose, CA) or FlowJo7 (Tree Star Inc., Ashland, OR) software.
Histomorphometry
Tibial specimens were fixed in 4% paraformaldehyde/PBS. For
histomorphometry, tibiae were embedded in methylmethacrylate
[32]. Five mm sagittal sections were stained with toluidine blue,
von Kossa stain, and safranin O and histomorphometry was
carried out in the secondary spongiosa of the proximal tibia as
previously described (OsteoMeasure
TM, OsteoMetrics, Decatur,
GA) [32].
Body composition
Body composition was measured by DEXA (Lunar PIXImus2;
GE Healthcare) and analysed using PIXImus2 software; the head
region was excluded from analyses.
Statistical Analyses
Statistical analyzes were performed using the nonparametric,
unpaired Mann-Whitney U test and the Long Rank (Mantel-Cox)
test using Graphpad Prism (San Diego, CA) software. P values of
,0.05 were considered significant.
Supporting Information
Table S1 Mendelian Analysis of the viability of
Ptpn2
ex22/ex22mice. Progeny from 16 heterozygous breeding
pairs were screened by PCR and the Mendelian ratio determined.
(DOCX)
Table S2 Gross phenotype of Ptpn2
2/2 (BALB/c),
Ptpn2
ex22/ex22 and Ptpn2
2/2 (C57BL/6) mice. Runtiness,
posture, piloerrection, diarrhoea and eye lid closure were assessed
in 18 day-old Ptpn2
2/2 (BALB/c), 28 day-old Ptpn2
ex22/ex22 and
28 day-old Ptpn2
2/2 (C57BL/6) mice.
(DOCX)
Acknowledgments
We thank Stephen Turner (The University of Melbourne, Australia),
Christina Mitchell (Monash University, Australia), Martin Lackmann
(Monash University, Australia) and Richard L. Boyd (Monash University,
Melbourne, Australia) for the provision of reagents.
Author Contributions
Conceived and designed the experiments: FW DIG NAS TT. Performed
the experiments: FW SHC CvV KK IJP TS KL. Analyzed the data: FW
DIG NAS TT. Contributed reagents/materials/analysis tools: MLT DIG
TT NAS. Wrote the paper: TT DIG NAS.
References
1. Tiganis T, Bennett AM (2007) Protein tyrosine phosphatase function: the
substrate perspective. Biochem J 402: 1–15.
2. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, et al. (2007) Robust
associations of four new chromosome regions from genome-wide analyses of type
1 diabetes. Nat Genet 39: 857–864.
3. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, et al. (2008) Shared
and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med
359: 2767–2777.
4. The Wellcome Trust Case Control Consortium (2007) Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447: 661–678.
5. Long SA, Cerosaletti K, Wan JY, Ho JC, Tatum M, et al. (2011) An
autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R
signaling in CD4(+) T cells. Genes Immun 12: 116–125.
6. van Vliet C, Bukczynska PE, Puryer MA, Sadek CM, Shields BJ, et al. (2005)
Selective regulation of tumor necrosis factor-induced Erk signaling by Src family
kinases and the T cell protein tyrosine phosphatase. Nat Immunol 6: 253–260.
7. Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, et al.
(2010) Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute
lymphoblastic leukemia. Nat Genet 42: 530–535.
8. Shimizu T, Miyakawa Y, Iwata S, Kuribara A, Tiganis T, et al. (2004) A novel
mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1:
role of TC-PTP in modulating signals downstream from the BCR-ABL fusion
protein. Exp Hematol 32: 1057–1063.
9. Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, et al. (2007) T-cell protein
tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large
B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol Cell Biol 27:
2166–2179.
10. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, et al. Meta-analysis of
genome-wide association studies in .80 000 subjects identifies multiple loci for
C-reactive protein levels. Circulation 123: 731–738.
11. Lee CF, Ling ZQ, Zhao T, Fang SH, Chang WC, et al. (2009) Genomic-wide
analysis of lymphatic metastasis-associated genes in human hepatocellular
carcinoma. World J Gastroenterol 15: 356–365.
12. Klingler-Hoffmann M, Fodero-Tavoletti MT, Mishima K, Narita Y,
Cavenee WK, et al. (2001) The protein tyrosine phosphatase TCPTP suppresses
the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth
factor receptor. J Biol Chem 276: 46313–46318.
13. Tiganis T, Kemp BE, Tonks NK (1999) The protein tyrosine phosphatase
TCPTP regulates epidermal growth factor receptor-mediated and phosphati-
dylinositol 3-kinase-dependent signalling. J Biol Chem 274: 27768–27775.
14. Tiganis T, Bennett AM, Ravichandran KS, Tonks NK (1998) Epidermal growth
factor receptor and the adaptor protein p52
Shc are specific substrates of T-cell
protein tyrosine phosphatase. Mol Cell Biol 18: 1622–1634.
15. Galic S, Hauser C, Kahn BB, Haj FG, Neel BG, et al. (2005) Coordinated
regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and
TCPTP. Mol Cell Biol 25: 819–829.
16. Galic S, Klingler-Hoffmann M, Fodero-Tavoletti MT, Puryer MA, Meng TC,
et al. (2003) Regulation of insulin receptor signaling by the protein tyrosine
phosphatase TCPTP. Mol Cell Biol 23: 2096–2108.
17. Fukushima A, Loh K, Galic S, Fam B, Shields B, et al. (2010) T-cell protein
tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to
regulate gluconeogenesis. Diabetes 59: 1906–1914.
18. Simoncic PD, Bourdeau A, Lee-Loy A, Rohrschneider LR, Tremblay ML, et al.
(2006) T-cell protein tyrosine phosphatase (Tcptp) is a negative regulator of
colony-stimulating factor 1 signaling and macrophage differentiation. Mol Cell
Biol 26: 4149–4160.
19. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ (2002) The
T cell protein tyrosine phosphatase is a negative regulator of janus family kinases
1 and 3. Curr Biol 12: 446–453.
20. Shields BJ, Hauser C, Bukczynska PE, Court NW, Tiganis T (2008) DNA
replication stalling attenuates tyrosine kinase signaling to suppress S phase
progression. Cancer Cell 14: 166–179.
21. ten Hoeve J, Ibarra-Sanchez MJ, Fu Y, Zhu W, Tremblay M, et al. (2002)
Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22:
5662–5668.
22. Yamamoto T, Sekine Y, Kashima K, Kubota A, Sato N, et al. (2002) The
nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-
6-mediated signaling pathway through STAT3 dephosphorylation. Biochem
Biophys Res Commun 297: 811–817.
23. Aoki N, Matsuda T (2002) A nuclear protein tyrosine phosphatase TC-PTP is
a potential negative regulator of the PRL-mediated signaling pathway:
dephosphorylation and deactivation of signal transducer and activator of
transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 16: 58–69.
24. Wiede F, Shields BJ, Chew SH, Kyparissoudis K, van Vliet C, et al. (2011) T cell
protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in
mice. J Clin Invest 121: 4758–4774.
Ptpn2-Deficient Mice
PLoS ONE | www.plosone.org 14 May 2012 | Volume 7 | Issue 5 | e3670325. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, et al. (1997) Impaired
bone marrow microenvironment and immune function in T cell protein tyrosine
phosphatase-deficient mice. J Exp Med 186: 683–693.
26. Heinonen KM, Nestel FP, Newell EW, Charette G, Seemayer TA, et al. (2004)
T cell protein tyrosine phosphatase deletion results in progressive systemic
inflammatory disease. Blood.
27. Hassan SW, Doody KM, Hardy S, Uetani N, Cournoyer D, et al. (2010)
Increased susceptibility to dextran sulfate sodium induced colitis in the T cell
protein tyrosine phosphatase heterozygous mouse. PLoS ONE 5: e8868.
28. Bourdeau A, Dube N, Heinonen KM, Theberge JF, Doody KM, et al. (2007)
TC-PTP-deficient bone marrow stromal cells fail to support normal B
lymphopoiesis due to abnormal secretion of interferon-c. Blood 109: 4220–4228.
29. Kaul A, Koster M, Neuhaus H, Braun T (2000) Myf-5 revisited: loss of early
myotome formation does not lead to a rib phenotype in homozygous Myf-5
mutant mice. Cell 102: 17–19.
30. Scacheri PC, Crabtree JS, Novotny EA, Garrett-Beal L, Chen A, et al. (2001)
Bidirectional transcriptional activity of PGK-neomycin and unexpected
embryonic lethality in heterozygote chimeric knockout mice. Genesis 30:
259–263.
31. Zee T, Settembre C, Levine RL, Karsenty G (2012) T-cell protein tyrosine
phosphatase regulates bone resorption and whole-body insulin sensitivity
through its expression in osteoblasts. Mol Cell Biol 32: 1080–1088.
32. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ (2006) Perinatal
testosterone surge is required for normal adult bone size but not for normal bone
remodeling. Am J Physiol Endocrinol Metab 290: E456–462.
33. Hogquist KA, Baldwin TA, Jameson SC (2005) Central tolerance: learning self-
control in the thymus. Nat Rev Immunol 5: 772–782.
34. Aliahmad P, Kaye J (2008) Development of all CD4 T lineages requires nuclear
factor TOX. J Exp Med 205: 245–256.
35. Samitas K, Lotvall J, Bossios A B cells: from early development to regulating
allergic diseases. Arch Immunol Ther Exp (Warsz) 58: 209–225.
36. Tsiftsoglou AS, Vizirianakis IS, Strouboulis J (2009) Erythropoiesis: model
systems, molecular regulators, and developmental programs. IUBMB Life 61:
800–830.
37. Geissmann F, Jung S, Littman DR (2003) Blood monocytes consist of two
principal subsets with distinct migratory properties. Immunity 19: 71–82.
38. Fayad R, Sennello JA, Kim SH, Pini M, Dinarello CA, et al. (2005) Induction of
thymocyte apoptosis by systemic administration of concanavalin A in mice: role
of TNF-a, IFN-c and glucocorticoids. Eur J Immunol 35: 2304–2312.
39. Loh K, Fukushima A, Zhang X, Galic S, Briggs D, et al. (2011) Elevated
hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell
Metab 14: 684–699.
40. LeCouter JE, Kablar B, Hardy WR, Ying C, Megeney LA, et al. (1998) Strain-
dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in
mice lacking the Rb-related p107 gene. Mol Cell Biol 18: 7455–7465.
41. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, et al. (1996)
Modulation of disease severity in cystic fibrosis transmembrane conductance
regulator deficient mice by a secondary genetic factor. Nat Genet 12: 280–287.
42. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, et al. (1997)
Mapping of a major genetic modifier of embryonic lethality in TGFb1 knockout
mice. Nat Genet 15: 207–211.
43. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, et al.
(1995) Targeted disruption of mouse EGF receptor: effect of genetic background
on mutant phenotype. Science 269: 230–234.
44. Sibilia M, Wagner EF (1995) Strain-dependent epithelial defects in mice lacking
the EGF receptor. Science 269: 234–238.
45. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH (2007) Rb regulates
interactions between hematopoietic stem cells and their bone marrow
microenvironment. Cell 129: 1081–1095.
46. Doody KM, Bussieres-Marmen S, Li A, Paquet M, Henderson JE, et al. (2011)
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis
and subchondral bone resorption in mice. Arthritis Rheum 64: 752–61.
47. Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, et al. (2000) Bone
homeostasis in growth hormone receptor-null mice is restored by IGF-I but
independent of Stat5. J Clin Invest 106: 1095–1103.
48. Moore KA, Lemischka IR (2006) Stem cells and their niches. Science 311:
1880–1885.
49. Adams GB, Scadden DT (2006) The hematopoietic stem cell in its place. Nat
Immunol 7: 333–337.
Ptpn2-Deficient Mice
PLoS ONE | www.plosone.org 15 May 2012 | Volume 7 | Issue 5 | e36703